A Study of Safety and Efficacy of CNTO 148 in Patients With Severe Persistent Asthma

Phase 2 Completed 309 enrolled Centocor, Inc.

RandomizedParallel-groupDouble-blindTreatment

The purpose of this study is to evaluate the effectiveness and safety of CNTO 148 (golimumab) in patients with severe persistent asthma.

Evaluation	Drug	Modality	Dose	Route
Subject	Golimumab	Monoclonal antibody	50 mg	Subcutaneous
Subject	Golimumab	Monoclonal antibody	75 mg	Subcutaneous
Subject	Golimumab	Monoclonal antibody	100 mg	Subcutaneous
Subject	Golimumab	Monoclonal antibody	150 mg	Subcutaneous
Subject	Golimumab	Monoclonal antibody	200 mg	Subcutaneous
Subject	Golimumab	Monoclonal antibody	300 mg	Subcutaneous